secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021715
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q3 revenue +22% to $26.3M; net income from continuing ops positive; THP discontinued
--------------------------------------------------------------------------------

- Q3 net revenue $26.3M (+22% YoY); net income from continuing ops $0.8M vs loss $0.2M; Adj. EBITDA $4.9M (+$2.3M).
- Soft tissue repair revenue +24% driven by CellerateRX and BIASURGE; gross margin improved to 93% from 91%.
- Operations of Tissue Health Plus (THP) ceased in Q3; $26.5M noncash impairment charge; THP classified as discontinued ops.
- Net loss from discontinued ops $31.2M in Q3; overall net loss $30.4M vs $2.9M loss YoY from continuing and disc ops.
- Seth Yon appointed CEO effective Sept 15, 2025; Ron Nixon remains Executive Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315225021715/0001493152-25-021715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315225021715/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer